Xenetic Biosciences (XBIO) Tax Provisions (2019 - 2021)
Xenetic Biosciences' (XBIO) quarterly Tax Provisions came in at $2.7 million in Q4 2020, up 1044.17% YoY from $234954.5 in Q1 2020, and up 192.11% on a QoQ basis from -$2.9 million in Q3 2020.
Xenetic Biosciences (XBIO) Tax Provisions (2019 - 2021) Analysis & Trends
Xenetic Biosciences (XBIO) has 2 years of Tax Provisions data on file, last reported at $2.7 million in Q4 2020.
- Quarterly Tax Provisions rose 1044.17% year-over-year to $2.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2021 was -$230238.0 (up 55.29% YoY) and the FY2020 annual result came in at -$230238.0, up 19.14% from the prior year.
- Tax Provisions advanced to $2.7 million in Q4 2020, from -$2.9 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $2.7 million in Q4 2020 to a low of -$2.9 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -1.19 Mn |
| Dec 31, 2020 | 2.69 Mn |
| Sep 30, 2020 | -2.92 Mn |
| Dec 31, 2019 | -284,724.00 |